Source link : https://www.newshealth.biz/health-news/semaglutide-equally-effective-in-women-with-hfpef-obesity/
ORLANDO, Fla. — Women with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without diabetes, derive the same benefit from the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide (Wegovy, Ozempic) as men did, according to a newly published analysis of data from two large international trials. In the prespecified secondary analysis, […]
Author : News Health
Publish date : 2024-06-24 22:23:28
Copyright for syndicated content belongs to the linked Source.
Categories